Nabla Technologies, whose clinical AI copilot is redefining healthcare workflows by automating medical documentation, reducing clinician burnout, and accelerating digital transformation across hospitals worldwide, has raised $70 million.

The Series C funding is led by HV Capital, with additional backing from Highland Europe, DST Global, and existing investors like Cathay Innovation. This round brings Nabla’s total funding to $120 million, allowing the company to accelerate the evolution of its AI copilot into more specialized AI agents.

These next-generation agents will expand beyond documentation to handle tasks such as real-time billing issue detection, retrieving historical medical data, and initiating workflows directly within electronic health records (EHRs).

Nabla’s clinical AI copilot, developed by the Paris and New York-based startup, is emerging as a vital solution in healthcare’s growing struggle with administrative overload. By automating tasks such as documentation and prescription generation, this AI tool helps clinicians reclaim time for patient care while simultaneously boosting system efficiency.

This innovation matters more now than ever. Physicians globally face mounting pressure from paperwork and burnout, and Nabla’s AI copilot eases that burden. It supports over 20 million patient interactions annually and serves more than 130 healthcare organizations globally.

From Voice to Action: Copilot’s Functionality

Nabla launched its AI copilot as a Chrome extension, utilizing GPT-3 to transcribe and restructure doctor-patient conversations into actionable medical documents, such as consultation summaries, prescriptions, and follow-up notes. The technology reduces the clerical workload by over 50 percent, thereby lowering both burnout and the risk of human error.

Soon, Nabla plans to roll out an in-person tool that further integrates real-time clinical data capture into physical consultations. The goal is to enable doctors to focus entirely on care delivery while the AI copilot handles the administrative tasks.

Co-founder and CEO Alexandre Lebrun’s vision is clear. Nabla’s AI copilot must blend seamlessly into clinical routines. Its success comes from being designed with healthcare professionals, not just for them. Collaborations with partner hospitals have helped shape features like nurse-focused flow sheet generators and a dictation tool launched earlier this year.

Now, Nabla is diving deeper into agentic AI. Their new clinical AI agents aim to deliver personalized, context-aware assistance, whether it’s supporting rural hospitals lacking medical staff or helping pediatric centers where documentation needs differ drastically.

Trust Through Precision and Speed

Despite initially using GPT-3, Nabla intends to develop its own large language model optimized for the specific needs of healthcare. CEO Lebrun admits the challenge, “We can’t afford a 5 percent error rate in clinical settings.” Therefore, the startup emphasizes rigorous accuracy and fine-tuned customization in its AI development.

This commitment has paid off. More than 85,000 clinicians, including 20,000 in the US, now trust Nabla’s technology for their day-to-day work. It’s a remarkable vote of confidence in a field where precision is paramount.

With a sharp fivefold increase in revenue over the last six months, Nabla proves that the demand for intelligent automation in healthcare is both urgent and scalable. From rural clinics to urban hospitals, the clinical AI copilot is no longer just a futuristic idea. It’s already reshaping how healthcare providers work, communicate, and deliver care.

“Clinicians already trust our accuracy and speed,” Lebrun said. “This funding allows us to expand that impact by embedding intelligent support directly into care delivery.”

Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.

We Recommend: